Fasting vs. cancer: A cellular uphill battle reversed – NaturalNews.com
Fasting vs. cancer: A cellular uphill battle reversed
Fasting has emerged as a promising ally in cancer treatment, according to groundbreaking research published in Immunity. A mouse study led by Memorial Sloan Kettering Cancer Center (MSK) revealed that fasting for 24-hour periods twice a week reprograms natural killer (NK) cells, enhancing their ability to infiltrate tumors and combat cancer. These findings, coupled with related clinical trials in humans, suggest that dietary adjustments could amplify cancer therapies’ efficacy—critical as therapeutic approaches grow more sophisticated.
The study found that fasting reconfigures NK cells’ metabolism, enabling them to thrive in tumor environments starved of glucose—a typical energy source for immune cells. By switching to fatty acids, NK cells increased production of interferon-gamma (IFN-?), a powerful cytokine that suppresses tumor growth. “Tumors are very hungry,” said senior author Dr. Joseph Sun, emphasizing how fasting trains NK cells to survive metabolic stress. This metabolic reprogramming could also improve immune responses to therapies like immunotherapy, though further clinical trials are needed to confirm these effects in humans.
How fasting reprograms the body’s cancer defensesNK cells, a key component of the body’s innate immune system, can recognize and destroy cancer cells without prior exposure to them. The MSK study demonstrated that fasting induces metabolic flexibility: Mice subjected to cyclic fasting experienced a drop in blood glucose, prompting NK cells in the spleen and bone marrow to adapt by metabolizing fatty acids.
In the bone marrow, fasting amplified IL-12 signaling—a cytokine pathway crucial for activating IFN-? production—while spleen-based NK cells became metabolically agile, leveraging fatty acids to sustain their cytotoxic activity. “The fasting acts like a training ground for NK cells,” explained lead author Dr. Rebecca Delconte. “They learn to thrive in hostile environments.”
These metabolic shifts had measurable effects: fasted mice developed smaller tumors and fewer metastases compared to control groups. A small human trial using a five-day fasting-mimicking diet (500–600 calories/day) alongside chemotherapy corroborated the mouse findings. Patients showed improved antitumor immunity, though long-term outcomes on cancer progression remain unclear.
Balancing nutrition: Dietary strategies for optimal healthWhile the body’s natural autophagy process—which breaks down cellular waste—benefits from fasting, healthcare professionals caution against extreme measures. Dr. Liao Zhiying, a radiation oncologist cited in the AP reports, noted strategies like “168” intermittent fasting (16 hours of fasting daily) or extended water fasts (3–5 days) can safely promote autophagy.
“A simulated fasting diet provides essential nutrients to sustain normal cells,” Liao explained, emphasizing that patients should avoid unguided regimens. He described his own experience with a five-day 600-calorie-a-day diet, which caused initial fatigue but improved endurance after metabolic adaptation. Beyond fasting, he highlighted restricting asparagine—an amino acid often sourced from the body—to deprive cancer cells of growth nutrients while boosting immune efficiency.
The Taiwanese study in Nature Metabolism corroborated this, showing reduced asparagine intake shrinks nasopharyngeal tumors and enhances memory T-cell activity. However, harnessing its clinical potential remains months away, as studies evaluate how to safely block asparagine synthesis without harming healthy cells.
Ethics and science: A tale of promising progress and retractionEven as fasting research gains traction, the scientific community faces reminders of the importance of rigorous validation. A landmark 2006 Alzheimer’s study, which proposed beta-amyloid-based therapies, is now undergoing retraction after Nature acknowledged falsified microscopic images in the study. The senior editor of the paper confirmed the issue on PubPeer, an online forum for scientific debate, underscoring the risks of compromised research.
“This contrasts sharply with the fasting studies, where findings were replicated across species,” said Dr. May Daher of MD Anderson Cancer Center, who collaborates on immune therapy. “But it’s a wake-up call to ensure every step of medical innovation withstands scrutiny.”
Toward clinics: Balancing hope and cautionDr. Neil Iyengar of MSK, an expert in diet and oncology, stressed that fasting’s promise must be balanced with individual health needs. “Patients undergoing treatment shouldn’t eliminate food without a doctor’s input,” he warned. Though meta-analyses suggest fasting’s safety for most healthy adults, cancer patients require personalized regimens to avoid malnourishment or fatigue.
Future research aims to identify drugs or external NK cell therapies that mimic fasting’s effects, sidestepping dietary requirements. However, until phase-three trials conclude, fasting remains experimental. “This is [likely] translatable to humans,” Delconte said, “but the jury is still out.”
A new chapter in cancer’s cellular warFasting’s capacity to reprogram immune cells has opened a new frontier in oncology, yet its path to routine use is cautious and winding. For now, the emphasis is on collaboration—between patient, physician and researcher—to tread the fine line between progress and peril.
Sources for this article include: